Domperidone - Risk of Cardiac Disorders (Products include Domerid/Motilium)
17 February 2012
The risk of QTc prolongation and cardiac risk with domperidone was previously reviewed at EU level by the Pharmacovigilance Working Party (PhVMP) of the European Medicines Agency, with the product information updated to reflect the available data at that time (2008).
Domperidone - Risk of Cardiac Disorders (Products include Domerid/Motilium)